Cardiovascular Polypill

Phase 3Small molecule

FFundación Centro Nacional de Investigaciones Cardiovasculares Carlos III

Cardiovascular Polypill is one of 55 small molecule programs targeting Cardiovascular Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cardiovascular DiseaseRecruiting

Cardiovascular DiseasePhase 3

Recruiting

Competition

Competitive Landscape

147 competitors in Cardiovascular Disease

#DrugCompanyPhaseTrials

Actemra

Roche

Approved

1 2

Lexiscan

Thalitone

Dobutrex

Isordil

Atacand

IIstituto Clinico Humanitas

Approved

—7

Bumex

VValidus Pharmaceuticals

Colcrys

1 9

Pelacarsen

Novartis

Phase 3

1 10

Cagrilintide

Novo Nordisk

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2031

Phase 3Recruiting

Cardiovascular Disease

NCT06930885

Clinical

Trials by Indication[1]

Cardiovascular Disease2 trials

Secondary Prevention of Cardiovascular Disease in the Elderly Trial

Completed·FFundación Centro Nacional de Investigaciones Cardiovasculares Carlos III·Phase 3·NCT02596126·2,499 enrolled

Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease

Recruiting·HHospital do Coracao·Phase 3·NCT06930885·7,713 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Cardiovascular Polypill. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cardiovascular Polypill compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cardiovascular Polypill. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: FFundación Centro Nacional de Investigaciones Cardiovasculares Carlos III

Cardiovascular Polypill

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2031

Trials by Indication[1]

Cardiovascular Disease2 trials

References

Drug Info

Quick Facts

Related News